Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial

Chengshui Chen; Xinyu Liang; Zheng Peng; Yan Zou; Huijuan He; Xiaoyan Zhang; Yi He; Shixiu Wu

doi:10.1001/jamaoncol.2026.0136

Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial

JAMA Oncol. 2026 Mar 5:e260136. doi: 10.1001/jamaoncol.2026.0136. Online ahead of print.

Authors

Chengshui Chen¹, Xinyu Liang¹, Zheng Peng¹, Yan Zou¹, Huijuan He¹, Xiaoyan Zhang², Yi He², Shixiu Wu¹

Affiliations

¹ The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
² Zhejiang Engineering Research Center for Intelligent Manufacturing of Clinical Diagnostic Equipment, Hangzhou, China.

No abstract available

Plain language summary

This nonrandomized clinical trial examines the safety and efficacy of oral upadacitinib in the treatment of patients with severe immune checkpoint inhibitor–related dermatitis.